ticlopidine has been researched along with alprostadil in 34 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (11.76) | 18.7374 |
1990's | 8 (23.53) | 18.2507 |
2000's | 10 (29.41) | 29.6817 |
2010's | 12 (35.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Cazenave, JP; Defreyn, G; Driot, F; Gachet, C; Maffrand, JP; Savi, P | 1 |
Bouloux, C; Cazenave, JP; Defreyn, G; Driot, F; Gachet, C; Maffrand, JP; Ohlmann, P | 1 |
Jönsson, BA; Norgren, L; Strand, SE; Thörne, LJ | 1 |
Charbonnier, R; Pistone, MA; Resegotti, L; Testa, D; Toselli, P; Vivalda, S | 1 |
Battais, E; Bonne, C | 1 |
Aubert, D; Ferrand, C; Loubrie, JC; Tuong, A; Tuong, CC | 1 |
Akkawat, B; Cattaneo, M; Cimminiello, C; Kinlough-Rathbone, RL; Mannucci, PM; Packham, MA | 1 |
Kirichenko, AA; Prekina, VI | 1 |
Fukushi, H; Imura, Y; Kawamura, M; Kita, S; Moriya, N; Nishikawa, K; Sugihara, H; Terashita, Z | 1 |
Reimann, S; Schrör, K; Weber, AA | 1 |
Brich, J; Eigenthaler, M; Geiger, J; Herbert, JM; Hönig-Liedl, P; Schanzenbächer, P; Walter, U | 1 |
Belcher, G; Horrocks, M; Watson, HR | 1 |
Fischer, M; Marsch, WC; Wohlrab, J | 1 |
Akimaru, S; Ito, H; Katsube, N; Maegawa, H; Marsala, M; Nakai, K; Takenobu, Y; Takimizu, H | 1 |
Behan, MW; Fox, SC; Heptinstall, S | 1 |
Atar, D; Defranco, A; Mahmud, E; Malinin, A; Pokov, A; Schwartz, D; Schwartz, K; Serebruany, V; Spergling, M | 1 |
Asai, F; Hagihara, K; Hashimoto, M; Jakubowski, JA; Kurihara, A; Niitsu, Y; Ogawa, T; Sugidachi, A | 1 |
Ishikawa, O; Nagai, Y; Okada, E | 1 |
Diodati, JG; Lordkipanidzé, M; Nguyen, TA; Pharand, C; Schampaert, E | 1 |
Price, MJ; Teirstein, PS | 1 |
Gouya, G; Jilma, B; Siller-Matula, JM; Wolzt, M | 1 |
Desta, Z; Flockhart, DA; Jin, Y; Kovacs, R; Kreutz, RP; Kreutz, Y; Miao, J; Nystrom, P | 1 |
Bauersachs, J; Flierl, U; Fraccarollo, D; Lausenmeyer, E; Massberg, S; Rosenstock, T; Schäfer, A; Schulz, C | 1 |
Khachikyan, MV; Khaspekova, SG; Mazurov, AV; Ruda, MY; Yakushkin, VV; Zyuryaev, IT | 1 |
Bagoly, Z; Csiba, L; Kappelmayer, J; Magyar, T; Muszbek, L; Pongrácz, E; Sarkady, F | 1 |
Dhillon, K; Dovlatova, N; Fox, SC; Glenn, JR; Heptinstall, S; White, AE | 1 |
Curzen, N; Englyst, N; Hobson, A; Khanna, V; Mikael, R; Sambu, N | 1 |
Galuszka, J; Hlusi, A; Hutyra, M; Indrak, K; Indrakova, J; Krcova, V; Slavik, L; Ulehlova, J | 1 |
Chirkov, YY; De Caterina, R; Horowitz, JD; Hurst, NL; Nooney, VB | 1 |
Lee, JH; Park, TK; Shin, SJ | 1 |
3 review(s) available for ticlopidine and alprostadil
Article | Year |
---|---|
[Ticlid : clinical use and current concepts about the mechanism of action].
Topics: Alprostadil; Hemostasis; Humans; Platelet Aggregation; Platelet Membrane Glycoproteins; Thrombosis; Ticlopidine; Treatment Outcome | 1993 |
Adjuvant medical therapy in peripheral bypass surgery.
Topics: Alprostadil; Anticoagulants; Aspirin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dextrans; Double-Blind Method; Femoral Artery; Heparin, Low-Molecular-Weight; Humans; Iloprost; Ischemia; Leg; Platelet Aggregation Inhibitors; Popliteal Artery; Prospective Studies; Randomized Controlled Trials as Topic; Ticlopidine; Vascular Surgical Procedures | 1999 |
[Current therapy of Sneddon's syndrome].
Topics: Alprostadil; Antihypertensive Agents; Blood Circulation; Captopril; Fibrinolytic Agents; Humans; Prognosis; Risk Factors; Smoking; Sneddon Syndrome; Ticlopidine | 2001 |
3 trial(s) available for ticlopidine and alprostadil
Article | Year |
---|---|
Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Alprostadil; Blood Platelets; Clopidogrel; Coronary Disease; Female; Humans; Male; Middle Aged; Monitoring, Physiologic; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2 Receptor Agonists; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y1; Stents; Thrombosis; Ticlopidine | 2007 |
Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition.
Topics: Adenosine Diphosphate; Adult; Alprostadil; Clopidogrel; Double-Blind Method; Female; Humans; Male; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prospective Studies; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Sample Size; Ticlopidine | 2008 |
Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers.
Topics: Adenosine Diphosphate; Adult; Alprostadil; Arachidonic Acid; Aspirin; Clopidogrel; Electrodes; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Ticlopidine; Time Factors; Young Adult | 2009 |
28 other study(ies) available for ticlopidine and alprostadil
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits.
Topics: Adenosine Diphosphate; Adenylyl Cyclases; Alprostadil; Animals; Blood Platelets; Clopidogrel; Enzyme Activation; Female; In Vitro Techniques; Platelet Aggregation Inhibitors; Rabbits; Rats; Rats, Inbred Strains; Stereoisomerism; Ticlopidine | 1991 |
The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1.
Topics: Adenosine Diphosphate; Adenylyl Cyclases; Alprostadil; Bleeding Time; Blood Platelets; Calcium; Cyclic AMP; Cytoplasm; Enzyme Activation; Epinephrine; Humans; In Vitro Techniques; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 1990 |
Effect of ticlopidine and prostaglandin E on endotoxin-induced pulmonary platelet sequestration in vivo.
Topics: Alprostadil; Animals; Anticoagulants; Blood Platelets; Endotoxins; Indium; Lung; Platelet Aggregation; Platelet Count; Rabbits; Radionuclide Imaging; Shock, Septic; Ticlopidine | 1986 |
[Bone marrow culture in patients treated with Ticlopidine].
Topics: Adult; Aged; Agranulocytosis; Alprostadil; Anticoagulants; Bone Marrow; Cells, Cultured; Colony-Forming Units Assay; Female; Granulocytes; Humans; Male; Middle Aged; Prostaglandins E; Thiophenes; Ticlopidine | 1985 |
Ticlopidine and adenylate cyclase.
Topics: Adenylyl Cyclases; Alprostadil; Animals; Blood Platelets; Enzyme Activation; Male; Prostaglandins E; Rabbits; Rats; Rats, Inbred Strains; Thiophenes; Ticlopidine | 1984 |
Modulation of the inhibitory action of prostaglandin E1 on platelet aggregation in rats: a study with ticlopidine, aspirin, dipyridamole and sulfinpyrazone.
Topics: Adenosine Diphosphate; Alprostadil; Animals; Aspirin; Dipyridamole; Male; Phosphorylation; Platelet Aggregation; Prostaglandins E; Rats; Rats, Inbred Strains; Sulfinpyrazone; Thiophenes; Ticlopidine | 1982 |
Ticlopidine facilitates the deaggregation of human platelets aggregated by thrombin.
Topics: Adenosine Diphosphate; Aged; Alprostadil; Chymotrypsin; Female; Fibrinolysin; Hirudins; Humans; Male; Middle Aged; Platelet Aggregation; Thrombin; Ticlopidine | 1994 |
Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
Topics: Alprostadil; Animals; Arginine; Aspirin; Clopidogrel; Dogs; Fibrinolytic Agents; Guanidines; Guinea Pigs; Humans; Macaca fascicularis; Male; Pipecolic Acids; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrazines; Sulfonamides; Ticlopidine | 1996 |
Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.
Topics: Adenosine Diphosphate; Alprostadil; Apyrase; Blood Platelets; Clopidogrel; Cyclic AMP; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Serum Albumin; Stereoisomerism; Ticlopidine; Time Factors | 1999 |
Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel.
Topics: Adenosine Diphosphate; Adult; Alprostadil; Blood Platelets; Calcium; Clopidogrel; Cyclic AMP; Epinephrine; Female; Humans; Male; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Ticlopidine; Vasodilator Agents | 1999 |
Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol.
Topics: Alprostadil; Animals; Body Weight; Cilostazol; Disease Models, Animal; Exercise Test; Intermittent Claudication; Male; Nifedipine; Platelet Aggregation; Rats; Rats, Wistar; Skin; Spinal Cord; Tetrazoles; Ticlopidine; Time Factors; Walking | 2003 |
Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Alprostadil; Calcium; Calcium Signaling; Clopidogrel; Cytoplasm; Dose-Response Relationship, Drug; Drug Synergism; Humans; Membrane Proteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine; Time Factors | 2004 |
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.
Topics: Adenosine Diphosphate; Alprostadil; Animals; Blood Platelets; Clopidogrel; Cyclic AMP; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Rats; Rats, Sprague-Dawley; Thiophenes; Ticlopidine | 2007 |
A case of widespread livedoid vasculopathy with pain but no systemic symptoms.
Topics: Adult; Alprostadil; Aspirin; Biopsy; Blood Sedimentation; C-Reactive Protein; Female; Humans; Hyperesthesia; Lymphocytes; Platelet Aggregation Inhibitors; Skin; Skin Diseases, Vascular; Ticlopidine; Vasodilator Agents | 2008 |
Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers.
Topics: Adenosine Diphosphate; Adult; Alprostadil; Blood Platelets; Clopidogrel; Drug Monitoring; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Point-of-Care Systems; Recovery of Function; Ticlopidine | 2008 |
Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.
Topics: Adenosine Diphosphate; Aged; Alprostadil; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Diabetes Mellitus; Female; Genotype; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticlopidine | 2013 |
Fractalkine activates a signal transduction pathway similar to P2Y12 and is associated with impaired clopidogrel responsiveness.
Topics: Adenosine Diphosphate; Alprostadil; Chemokine CX3CL1; Clopidogrel; Coronary Artery Disease; Humans; Phosphatidylinositol 3-Kinases; Phosphorylation; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Ticlopidine | 2012 |
Spontaneous platelet aggregation in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Alprostadil; Antibodies; Aspirin; Blood Platelets; Clopidogrel; Humans; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Ticlopidine; von Willebrand Factor | 2013 |
Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy.
Topics: Adenosine Diphosphate; Adult; Aged; Alprostadil; Blood Platelets; Cell Adhesion Molecules; Clinical Laboratory Techniques; Clopidogrel; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Reproducibility of Results; Stroke; Ticlopidine | 2013 |
'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists.
Topics: Adenosine; Adenosine Diphosphate; Alprostadil; Biomarkers, Pharmacological; Blood Platelets; Bucladesine; Cell Adhesion Molecules; Cells, Cultured; Clopidogrel; Cyclic AMP; Humans; Iloprost; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Reproducibility of Results; Sensitivity and Specificity; Thiophenes; Thrombophilia; Ticlopidine | 2014 |
Does the VerifyNow P2Y12 assay overestimate "therapeutic response" to clopidogrel? Insights using short thrombelastography.
Topics: Adenosine Diphosphate; Alprostadil; Clopidogrel; Drug Synergism; Humans; Platelet Aggregation; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombelastography; Ticlopidine | 2014 |
Detection of clopidogrel resistance using ADP induced aggregometry with specific inhibitor PGE1.
Topics: Adenosine Diphosphate; Adult; Aged; Alprostadil; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Ticlopidine; Treatment Outcome | 2014 |
Determinants of subacute response to clopidogrel: relative impact of CYP2C19 genotype and PGE1/adenylate cyclase signalling.
Topics: Adenylyl Cyclases; Adult; Aged; Aged, 80 and over; Alprostadil; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Signal Transduction; Ticlopidine | 2015 |
Effect of Drugs Associated With Bleeding Tendency on the Complications and Outcomes of Transforaminal Epidural Steroid Injection.
Topics: Aged; alpha-Cyclodextrins; Alprostadil; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Injections, Epidural; Male; Middle Aged; Pain; Pain Measurement; Platelet Aggregation Inhibitors; Retrospective Studies; Steroids; Ticlopidine; Time Factors; Treatment Outcome | 2017 |